Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Dozeman

Internal Medicine Holland, MI Doctor of Osteopathy

NPI 1134332794 CMS profile 187188

588 E Lakewood Blvd, Holland, MI 49424

Open in the dashboard

General payments

$4,100

258 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Dozeman of Holland, MI is reported in the CMS Open Payments database as having received $4,100 across 258 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $515 27
2024 General $772 45
2023 General $767 51
2022 General $370 29
2021 General $76 3
2020 General $410 26
2019 General $1,190 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Dozeman
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Benjamin Dozeman were reported at $515. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Benjamin Dozeman Internal Medicine median Middle half National median
2019 $1,190 $159 $48–$570 $163
2020 $410 $119 $33–$402 $114
2021 $76 $135 $37–$521 $132
2022 $370 $141 $42–$496 $149
2023 $767 $149 $45–$519 $160
2024 $772 $154 $47–$537 $164
2025 $515 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,036 60 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $773 52 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $392 28 payments
  4. Pfizer Inc. $371 27 payments
  5. Celgene Corporation $291 33 payments
  6. Shionogi Inc $204 8 payments
  7. Janssen Biotech, Inc. $178 8 payments
  8. UCB, Inc. $153 10 payments
  9. Intercept Pharmaceuticals, Inc. $130 5 payments
  10. Regeneron Healthcare Solutions, Inc. $123 5 payments
  11. Other $448 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,058 254 payments
  2. Education $42 4 payments
Products named General payments · program years 2019–2025
  1. ENTYVIO $601 39 payments
  2. RINVOQ $560 29 payments
  3. HUMIRA $395 21 payments
  4. XIFAXAN $392 28 payments
  5. XELJANZ $371 27 payments
  6. ZEPOSIA $342 34 payments
  7. SKYRIZI Immunology $282 18 payments
  8. Mulpleta $204 8 payments
  9. Cimzia $153 10 payments
  10. SKYRIZI Immunology $152 11 payments
  11. Other $1,533 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,065

Median for Gastroenterology: 569

Drug cost

$634,396

Median for Gastroenterology: $104,976

Branded share of claims

48.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi On-Body Risankizumab-Rzaa Brand 12 $214,788
Humira(Cf) Pen Adalimumab Brand 18 $157,560
Rinvoq Upadacitinib Brand 15 $101,167
Xeljanz Xr Tofacitinib Citrate Brand 11 $72,892
Mesalamine Generic 48 $29,275
Mesalamine Er Mesalamine Brand 26 $13,806
Linzess Linaclotide Brand 19 $11,220
Balsalazide Disodium Generic 46 $8,929
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 329 $7,912
Budesonide Dr Budesonide Brand 54 $4,885

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$31,291

Medicare's payments for the services billed

Medicare patients

188

Average age 71

Services billed

260

111 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 46%
Depression 26%
Ischemic heart disease 20%
Diabetes 18%
Chronic kidney disease 17%
Atrial fibrillation 15%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $309
$309 — —
DUPIXENT
  • GENZYME CORPORATION $76
  • Regeneron Healthcare Solutions, Inc. $75
$151 — —
RINVOQ
  • AbbVie, Inc. $81
$81 15 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $67
$67 — —
SKYRIZI
  • AbbVie, Inc. $52
$52 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

258 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record